REGISTRY OF THE EUROPEAN REFERENCE NETWORK ON RARE ADULT SOLID CANCERS

  • Research type

    Research Database

  • IRAS ID

    347880

  • Contact name

    Thuy-Giang Nguyen

  • Contact email

    thuy-giang.nguyen@rmh.nhs.uk

  • Research summary

    REGISTRY OF THE EUROPEAN REFERENCE NETWORK ON RARE ADULT SOLID CANCERS “EURACAN”

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    25/EE/0059

  • Date of REC Opinion

    16 May 2025

  • REC opinion

    Further Information Favourable Opinion

  • Data collection arrangements

    Core data elements will include the "Set of common data elements for Rare Disease Registration" developed by JRC (https://eu-rd-platform.jrc.ec.europa.eu/set-of-common-data-elements) to address specificities of rare cancers as compared to rare diseases.
    Following the EURACAN registry objectives, data will be prospectively collected on patient characteristics, exposure and outcomes. Patient characteristics will consist of descriptive patient data, such as information on patient demographics, including race, lifestyle, medical history, health status, etc. Exposure data will focus on the disease, devices, procedures, treatments or services of interest. Outcome data will describe patient outcomes (e.g. survival, progression, progression-free survival, death, etc.). In addition, data on potential confounders will also be collected.

  • Research programme

    In order to support the development of registries within ERNs, the European Commission decided to set up a European Platform on Rare Disease Registration (EU RD Platform) and to develop specific standards for the interoperability of rare disease registries, drawn up by the Commission's Joint Research Centre (JRC). The EU RD Platform makes rare disease registry data searchable and findable, thus increasing the visibility of each registry. This is ensured by the European RD Registry Infrastructure (ERDRI), which supports the activities of existing and the creation of new registries. The EURACAN registry will be fully compliant with ERDRI requirements, to ensure its interoperability with other rare disease registries, and will be enrolled in ERDRI. The EURACAN registry will therefore be registered in the EU RD Platform. In addition, synergies with other ERN registries will be fostered through the ERN Registries Task Force. Opportunities for partnerships with population-based CRs will also be explored. Finally, the EURACAN registry will be interoperable with the Clinical Patient Management System (CPMS), i.e. the tool developed by the Commission to provide multidisciplinary second opinions for complex case management (i.e. teleconsulations across different expert centres).

  • Research database title

    REGISTRY OF THE EUROPEAN REFERENCE NETWORK ON RARE ADULT SOLID CANCERS “EURACAN”

  • Establishment organisation

    The Royal Marsden Hospital

  • Establishment organisation address

    203 Fulham Road

    London

    SW3 6JJ